This is a multi-center, randomized, double-blind, placebo-controlled study in approximately 104 subjects (52 per group) to evaluate the effectiveness of an herb and mineral combination product on fasting serum glucose levels in subjects with impaired fasting glucose. The study consists of 5 visits: a Screening visit, followed by a Baseline visit (at which eligible subjects will be randomized to product to consume throughout the 12-week supplementation period), followed by Supplementation period visits at 3, 6 and 12 weeks after baseline.

The target population of this clinical trial is otherwise healthy, pre-diabetic adults who present with impaired fasting glucose.

Inclusion Criteria:

• Be male or female, at least 18 years of age
• If age ≥45 years, must have a body mass index ≥ 25 kg/m2
• If age <45 years, must have a body mass index ≥ 25 kg/m2 AND present with at least one additional risk factors for developing diabetes.
• Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (women only)
• Be able to understand the nature and purpose of the study including potential risks and side effects
• Be willing to consent to study participation and to comply with study requirements
• Have a finger stick fasting blood glucose between 105 and 140 mg/dL and a serum fasting glucose between 100 and 125 mg/dL, measured at screening

Exclusion Criteria:

• Have diabetes (type I or II) or an HBA1c measurement >6.5% at any time in the past or at the screening visit
• Have been taking within 2 weeks of screening any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose metabolism
• Have been taking within 4 weeks of screening any prescription or over-the-counter (OTC) medication that significantly affects glucose metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors), systemic corticosteroids
• Daily use of non-steroidal anti-inflammatory drugs (NSAIDS) (daily baby aspirin use and continuous use of NSAIDS for 3 days or less for acute aches and pains are acceptable)
• Any co-morbidity or treatment that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
• Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
• Eating disorder
• Polycystic ovary syndrome
• Known allergies or intolerance to any substance in the study product
• Are pregnant or breastfeeding women
• History of alcohol, drug, or medication abuse
• Have participated in another study with any investigational product within 1 month of screening
• Had a recent (<3 months) gastrointestinal surgery or any planned surgery during the clinical study